2023-05-09 07:03:13 ET
- Esperion Therapeutics press release ( NASDAQ: ESPR ): Q1 GAAP EPS of -$0.79 misses by $0.14 .
- Revenue of $24.33M (+29.2% Y/Y) beats by $2.36M .
-
U.S. net product revenue was $17.0 million, compared to $13.4 million for the comparable period in 2022, an increase of approximately 27%, driven by retail prescription growth of 15%.
Collaboration revenue was $7.3 million, compared to $5.5 million for the comparable period in 2022, an increase of 33%, driven by increased tablet sales to our international partners and sales growth within partner territories.
For further details see:
Esperion Therapeutics GAAP EPS of -$0.79 misses by $0.14, revenue of $24.33M beats by $2.36M